Urs Naber

Urs Naber's Title

Urs Naber is the Co-founder and Chief Medical Officer (CMO) at Zeit Medical. His role encompasses managing operations, fostering patient and clinical relationships, and structuring the company's regulatory path. With a deep understanding of both clinical care and medical technologies, Urs holds a pivotal position in steering Zeit Medical towards innovative healthcare solutions.

Urs Naber's Education and Expertise

Urs Naber is a highly qualified pediatric critical care physician with over a decade of clinical care experience. He has been involved in groundbreaking bench top, clinical, and educational research at prestigious institutions such as Dartmouth and Stanford University. His expertise extends to the development of pediatric medical devices, a field in which he has made significant contributions prior to joining the Stanford Biodesign Fellowship program.

Urs Naber's Background

Urs Naber has a diverse and rich background in the medical field, particularly focused on pediatric critical care. He has worked in various capacities, including participating in bench top and clinical research and developing medical devices for pediatric care. His international experience includes working in Shanghai and Beijing with a med-tech focused private equity firm, adding a global perspective to his expertise. Currently, he maintains a clinical role in the pediatric critical care unit of Valley Children's, ensuring he stays connected to direct patient care.

Urs Naber's Achievements

Throughout his career, Urs Naber has achieved notable milestones. His research at Dartmouth and Stanford has contributed to advancements in clinical and educational methodologies. He has also played a crucial role in the development of several pediatric medical devices, showcasing his ability to bridge clinical needs with technological solutions. His tenure at the Stanford Biodesign Fellowship program further underscores his commitment to creating impactful healthcare innovations. Additionally, his work with a med-tech private equity company in China highlights his versatility and global outlook on medical technology and regulatory frameworks.